1. Home
  2. OOMA vs ARVN Comparison

OOMA vs ARVN Comparison

Compare OOMA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

HOLD

Current Price

$20.02

Market Cap

517.6M

Sector

Technology

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.03

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OOMA
ARVN
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.6M
516.2M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
OOMA
ARVN
Price
$20.02
$8.03
Analyst Decision
Strong Buy
Buy
Analyst Count
4
19
Target Price
$18.77
$15.05
AVG Volume (30 Days)
314.1K
647.9K
Earning Date
05-27-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
188.46
58.84
EPS
0.09
N/A
Revenue
$114,490,000.00
$262,600,000.00
Revenue This Year
$20.35
N/A
Revenue Next Year
$4.17
N/A
P/E Ratio
$215.11
N/A
Revenue Growth
9.53
N/A
52 Week Low
$9.79
$6.06
52 Week High
$21.96
$14.22

Technical Indicators

Market Signals
Indicator
OOMA
ARVN
Relative Strength Index (RSI) 55.63 42.94
Support Level $10.78 $7.90
Resistance Level $21.57 $8.90
Average True Range (ATR) 0.88 0.31
MACD -0.10 -0.01
Stochastic Oscillator 52.24 6.00

Price Performance

Historical Comparison
OOMA
ARVN

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: